Bioarctic

Bioarctic company information, Employees & Contact Information

Explore related pages

Related company profiles:

With patients in mind, we are committed to our vision: A world where since defeats severe brain diseases. BioArctic AB (publ) is an innovative Swedish biopharma company focusing on research and develop into neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. With world-leading science and strong collaborations, we create, develop, and provide innovative treatments for patients with severe brain diseases. BioArctic has also developed the BrainTransporter™ technology, which has the potential to actively transport antibodies and other biological molecules across the blood-brain barrier to enhance distribution in the brain and drug efficacy. Collaborations are of great importance to the company and partnering with global pharma companies is a key element of our strategy. Our project portfolio is broad and well-diversified, with the potential to significantly improve the health of patients. The company was founded in 2003 based on innovative research at Uppsala University.

Company Details

Employees
129
Founded
-
Address
Warfvinges Väg 35, Stockholm,stockholm County 112 51,sweden
Phone
46 86 95 69 30
Email
in****@****ctic.se
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Stockholm, Stockholm County
Looking for a particular Bioarctic employee's phone or email?

Bioarctic Questions

News

$802 Million Brain Drug Breakthrough: BioArctic's Technology Could Transform Neurological Treatment Delivery - Stock Titan

$802 Million Brain Drug Breakthrough: BioArctic's Technology Could Transform Neurological Treatment Delivery Stock Titan

BioArctic Launches Leqembi Treatment for Alzheimer’s in the Nordics - TipRanks

BioArctic Launches Leqembi Treatment for Alzheimer’s in the Nordics TipRanks

Is BioArctic AB (publ)'s (STO:BIOA B) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st

Is BioArctic AB (publ)'s (STO:BIOA B) Latest Stock Performance A Reflection Of Its Financial Health? simplywall.st

BioArctic CEO Gunilla Osswald is Alumnus of the Year - Uppsala universitet

BioArctic CEO Gunilla Osswald is Alumnus of the Year Uppsala universitet

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties - Finansavisen

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties Finansavisen

BioArctic and Eisai bring Leqembi closer to home with new subcutaneous version - Biostock

BioArctic and Eisai bring Leqembi closer to home with new subcutaneous version Biostock

BioArctic’s Alzheimer’s Treatment Recognized as Top Innovation by TIME - TipRanks

BioArctic’s Alzheimer’s Treatment Recognized as Top Innovation by TIME TipRanks

How Leqembi's Finnish Launch at BioArctic (OM:BIOA B) Has Changed Its Investment Story - simplywall.st

How Leqembi's Finnish Launch at BioArctic (OM:BIOA B) Has Changed Its Investment Story simplywall.st

Putting a brake on Alzheimer’s - Karolinska Institutet

Putting a brake on Alzheimer’s Karolinska Institutet

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's - Yahoo Finance

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's Yahoo Finance

BioArctic AB Sees Growth with Leqembi® and Novartis Partnership - TipRanks

BioArctic AB Sees Growth with Leqembi® and Novartis Partnership TipRanks

Novartis pens BioArctic pact worth $30M upfront to find new drug in neurodegeneration field - Fierce Biotech

Novartis pens BioArctic pact worth $30M upfront to find new drug in neurodegeneration field Fierce Biotech

Award for Alzheimer’s disease drug - Uppsala universitet

Award for Alzheimer’s disease drug Uppsala universitet

Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier - BioSpace

Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier BioSpace

Bioarctic's new era: Leqembi takes off, Novartis signs $802M deal - BioWorld MedTech

Bioarctic's new era: Leqembi takes off, Novartis signs $802M deal BioWorld MedTech

Novartis, BioArctic Reach Deal to Develop BrainTransporter Therapy for Neurodegeneration - Pharmaceutical Executive

Novartis, BioArctic Reach Deal to Develop BrainTransporter Therapy for Neurodegeneration Pharmaceutical Executive

Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B) - simplywall.st

Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B) simplywall.st

BioArctic: Interim Report for the period April - June 2025 - Yahoo Finance

BioArctic: Interim Report for the period April - June 2025 Yahoo Finance

BioArctic Partners with Novartis for Neurodegeneration Treatment - TipRanks

BioArctic Partners with Novartis for Neurodegeneration Treatment TipRanks

BioArctic AB Announces Formation of Nomination Committee for 2026 AGM - TipRanks

BioArctic AB Announces Formation of Nomination Committee for 2026 AGM TipRanks

Novartis secures US$30m+ licence option from BioArctic - European Biotechnology Magazine

Novartis secures US$30m+ licence option from BioArctic European Biotechnology Magazine

Major Share Sale Announcement: BioArctic's Original Founders Plan First-Time Partial Divestment of Holdings - Stock Titan

Major Share Sale Announcement: BioArctic's Original Founders Plan First-Time Partial Divestment of Holdings Stock Titan

BioArctic presents Nomination Committee - TradingView

BioArctic presents Nomination Committee TradingView

BioArctic’s Leqembi Iqlik Launches in U.S. for Alzheimer’s Maintenance - TipRanks

BioArctic’s Leqembi Iqlik Launches in U.S. for Alzheimer’s Maintenance TipRanks

Eisai will request reconsideration of initial decision for lecanemab in Australia - Stock Titan

Eisai will request reconsideration of initial decision for lecanemab in Australia Stock Titan

BioArctic inks license option collaboration with Novartis - The Pharma Letter

BioArctic inks license option collaboration with Novartis The Pharma Letter

BioArctic AB Stock: On Route To Solving Alzheimer's Disease (OTCMKTS:BRCTF) - Seeking Alpha

BioArctic AB Stock: On Route To Solving Alzheimer's Disease (OTCMKTS:BRCTF) Seeking Alpha

Biotech behind Alzheimer’s drug seeks partners for blood-brain barrier technology - Financial Times

Biotech behind Alzheimer’s drug seeks partners for blood-brain barrier technology Financial Times

Novartis and BioArctic sign collaboration and license deal (NVS) (NVS:NYSE) - Seeking Alpha

Novartis and BioArctic sign collaboration and license deal (NVS) (NVS:NYSE) Seeking Alpha

Eisai will seek re-examination of CHMP opinion för lecanemab - Stock Titan

Eisai will seek re-examination of CHMP opinion för lecanemab Stock Titan

Trio behind Alzheimer’s drug receives Uppsala University Innovation and Entrepreneurship Award - Uppsala universitet

Trio behind Alzheimer’s drug receives Uppsala University Innovation and Entrepreneurship Award Uppsala universitet

BioArctic AB - Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD - MarketScreener

BioArctic AB - Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD MarketScreener

European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease: BioArctic - Stock Titan

European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease: BioArctic Stock Titan

AbbVie Pulls Out of Partnership With BioArctic for Parkinson Disease Candidates, Including ABBV-0805 - NeurologyLive

AbbVie Pulls Out of Partnership With BioArctic for Parkinson Disease Candidates, Including ABBV-0805 NeurologyLive

Novartis and BioArctic sign collaboration agreement on BrainTransporter technology for neurological drug development - Express Pharma

Novartis and BioArctic sign collaboration agreement on BrainTransporter technology for neurological drug development Express Pharma

The most shorted life science stocks in the Nordic region - Biostock

The most shorted life science stocks in the Nordic region Biostock

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future” - Life Science Sweden

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future” Life Science Sweden

Top Bioarctic Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant